Thus O
, O
unlike O
Old O
World O
primates O
, O
cortisol O
in O
New O
World O
primates O
has O
only O
weak O
sodium O
- O
retaining O
potency O
because O
the O
aldosterone B
receptor I
has O
a O
low O
affinity O
for O
cortisol O
. O

In O
particular O
, O
naturally O
occurring O
sequence O
variation O
impacted O
transcription B
factor I
binding O
to O
an O
activating B
transcription I
factor I
/ O
cAMP B
response I
element I
binding I
( O
ATF B
/ O
CREB B
) O
binding O
site O
( O
located O
between O
the O
LEF B
- I
1 I
and I
distal I
NF I
- I
kappaB I
transcription I
factor I
binding I
sites I
) O
that O
we O
identified O
in O
previous O
studies O
of O
the O
HIV B
- I
1 I
LTR I
. O

Transcripts O
for O
CYP19 B
and O
HSD11K B
were O
not O
detected O
. O

Furthermore O
, O
the O
inhibition O
of O
B O
cell O
differentiation O
by O
CD40 B
engagement O
could O
not O
be O
overcome O
by O
either O
mitogens B
or O
cytokines B
, O
but O
could O
be O
reversed O
by O
antibodies O
that O
interfere O
with O
the O
CD40 B
/ O
gp39 B
interaction O
. O

Activated O
PBMCs O
also O
expressed O
lower O
levels O
of O
RXRalpha B
protein O
, O
and O
a O
DNA O
binding O
assay O
showed O
that O
the O
activation O
- O
induced O
loss O
of O
RXRalpha B
mRNA I
and O
protein O
expression O
correlated O
with O
the O
loss O
of O
DNA O
binding O
activity O
of O
this O
protein O
. O

We O
present O
evidence O
that O
the O
transition O
from O
G0 O
/ O
G1 O
to O
S O
phase O
of O
the O
cell O
cycle O
results O
in O
the O
down O
- O
regulation O
of O
RXRalpha B
expression O
and O
that O
cell O
cycle O
inhibitors O
, O
which O
block O
the O
cells O
in O
G1 O
phase O
, O
prevent O
this O
down O
- O
regulation O
. O

These O
observations O
indicate O
that O
the O
levels O
of O
RXRalpha B
expression O
in O
T O
lymphocytes O
are O
coupled O
to O
cell O
cycle O
progression O
, O
and O
there O
is O
tight O
regulatory O
control O
of O
RXRalpha B
expression O
during O
the O
transition O
from O
G0 O
/ O
G1 O
to O
S O
phase O
of O
the O
cell O
cycle O
. O

Matrix B
metalloproteinase I
expression O
in O
human O
breast O
cancer O
: O
an O
immunohistochemical O
study O
including O
correlation O
with O
cathepsin B
D I
, O
type B
IV I
collagen I
, O
laminin B
, O
fibronectin B
, O
EGFR B
, O
c B
- I
erbB I
- I
2 I
oncoprotein I
, O
p53 B
, O
steroid O
receptors O
status O
and O
proliferative O
indices O
. O

Matrix B
metalloproteinase I
s O
( O
MMPs B
) O
are O
a O
group O
of O
enzymes O
thought O
to O
be O
responsible O
for O
both O
normal O
connective O
tissue O
matrix O
remodelling O
and O
accelerated O
breakdown O
associated O
with O
tumour O
development O
. O

The O
current O
study O
aimed O
to O
investigate O
the O
immunohistochemical O
expression O
of O
matrix B
metalloproteinase I
3 I
( O
MMP B
- I
3 I
, O
stromelysin B
- I
1 I
) O
in O
correlation O
with O
the O
expression O
of O
Basement B
Membrane I
( I
BM I
) I
antigen I
( O
type B
IV I
collagen I
, O
laminin B
) O
, O
fibronectin B
, O
cathepsin B
D I
, O
p53 B
, O
c B
- I
erbB I
- I
2 I
, O
proliferative O
activity O
( O
Ki B
- I
67 I
, O
PCNA B
) O
, O
steroid O
receptor O
content O
as O
well O
as O
to O
the O
other O
conventional O
clinicopathological O
parameters O
in O
breast O
cancer O
. O

Manganous B
superoxide I
dismutase I
( O
MnSOD B
) O
is O
an O
antioxidant B
protective I
factor I
. O

The O
objectives O
of O
these O
studies O
were O
to O
investigate O
mechanisms O
for O
induction O
of O
an O
injurious B
factor I
( O
IL B
- I
8 I
) O
and O
a O
protective B
factor I
( O
MnSOD B
) O
in O
the O
HepG2 O
human O
hepatoma O
cell O
line O
. O

Both O
TNF B
and O
ethanol O
increased O
HepG2 O
cell O
MnSOD B
activity O
in O
short O
- O
term O
( O
72 O
hr O
) O
cultures O
with O
ethanol O
. O

However O
, O
after O
long O
- O
term O
( O
10 O
weeks O
) O
culture O
with O
ethanol O
, O
there O
was O
no O
induction O
of O
MnSOD B
by O
ethanol O
and O
there O
was O
a O
diminished O
induction O
of O
MnSOD B
in O
response O
to O
TNF B
. O

Further O
studies O
are O
needed O
to O
assess O
the O
effect O
of O
this O
diminished O
induction O
of O
MnSOD B
with O
chronic O
ethanol O
culture O
on O
HepG2 O
cell O
susceptibility O
to O
TNF O
cytotoxicity O
. O

Fibrillar B
forms I
of O
beta B
- I
amyloid I
( O
Abeta B
) O
, O
which O
are O
the O
primary O
constituents O
of O
senile O
plaques O
, O
have O
been O
shown O
to O
activate O
tyrosine O
kinase O
- O
dependent O
signal O
transduction O
cascades O
, O
resulting O
in O
inflammatory O
responses O
in O
microglia O
. O

However O
, O
the O
downstream O
signaling O
pathways O
mediating O
Abeta B
- O
induced O
inflammatory O
events O
are O
not O
well O
characterized O
. O

Abeta B
stimulated O
the O
rapid O
, O
transient O
activation O
of O
extracellular B
signal I
- I
regulated I
kinase I
1 I
( O
ERK1 B
) O
and O
ERK2 B
in O
microglia O
and O
ERK2 B
in O
THP1 O
monocytes O
. O

Importantly O
, O
the O
stress B
- I
activated I
protein I
kinases I
( O
SAPKs B
) O
were O
not O
significantly O
activated O
in O
response O
to O
Abeta B
. O

Downstream O
effectors O
of O
the O
MAPK O
signal O
transduction O
cascades O
include O
MAPKAP B
kinases I
, O
such O
as O
RSK1 B
and O
RSK2 B
, O
as O
well O
as O
transcription B
factors I
. O

Exposure O
of O
microglia O
and O
THP1 O
monocytes O
to O
Abeta B
resulted O
in O
the O
activation O
of O
RSK1 B
and O
RSK2 B
and O
phosphorylation O
of O
cAMP B
response I
element I
- I
binding I
protein I
at O
Ser133 O
, O
providing O
a O
mechanism O
for O
Abeta B
- O
induced O
changes O
in O
gene O
expression O

In O
driving O
T O
cell O
proliferation O
, O
IL B
- I
2 I
stimulates O
a O
new O
program O
of O
gene O
expression O
that O
includes O
proliferating B
cell I
nuclear I
antigen I
( O
PCNA B
) O
, O
a O
requisite O
processivity O
factor O
for O
DNA B
polymerase I
delta I
. O

In O
response O
to O
stress O
, O
heat B
shock I
factor I
1 I
( O
HSF1 B
) O
acquires O
rapid O
DNA O
binding O
and O
transient O
transcriptional O
activity O
while O
undergoing O
conformational O
transition O
from O
an O
inert O
non B
- I
DNA I
- I
binding I
monomer I
to O
active O
functional O
trimers O
. O

Lymphocytes O
from O
adult O
, O
neonatally O
DES O
- O
treated O
female O
mice O
have O
a O
reduced O
mitogen O
response O
to O
ConA B
and O
LPS B
( O
T B
and I
B I
cell I
mitogen I
) O
and O
the O
delayed O
type O
hypersensitivity O
response O
is O
depressed O
. O

Concentrations O
of O
cytosol B
and I
nuclear I
estrogen I
receptors I
( O
ERC B
and O
ERN B
, O
respectively O
) O
and O
progestin B
receptors I
( O
PRC B
and O
PRN B
) O
were O
also O
measured O
from O
endometrial O
biopsies O
taken O
on O
the O
24th O
day O
of O
the O
control O
and O
treatment O
cycle O
. O

Interleukin B
2 I
receptor I
( O
Tac B
antigen I
) O
expression O
in O
HTLV O
- O
I O
- O
associated O
adult O
T O
- O
cell O
leukemia O
. O

Normal O
resting O
T O
- O
cells O
and O
most O
leukemic O
T O
- O
cell O
populations O
do O
not O
express O
IL B
- I
2 I
receptors I
; O
however O
, O
the O
leukemic O
cells O
of O
the O
11 O
patients O
examined O
who O
had O
human O
T O
- O
cell O
lymphotropic O
virus O
- O
associated O
adult O
T O
- O
cell O
leukemia O
expressed O
the O
Tac B
antigen I
. O

The O
presence O
of O
anti B
- I
human I
glucocorticoid I
receptor I
antibodies I
was O
verified O
by O
: O
( O
a O
) O
adsorption O
of O
[ B
3H I
] I
TA I
- I
receptor I
- I
antibody I
complexes I
to O
Protein B
A I
; O
( O
b O
) O
a O
shift O
to O
higher O
apparent O
molecular O
weight O
in O
the O
elution O
position O
from O
Sephacryl O
S300 O
of O
[ B
3H I
] I
TA I
- I
receptor I
complexes I
incubated O
with O
immune O
serum O
; O
and O
( O
c O
) O
the O
ability O
of O
immune O
serum O
to O
displace O
[ B
3H I
] I
TA I
- I
receptor I
complexes I
on O
sucrose O
gradients O
. O

Administration O
of O
fibroblast B
interferon I
to O
patients O
with O
advanced O
breast O
cancer O
: O
possible O
effects O
on O
skin O
metastasis O
and O
on O
hormone B
receptors I
. O

Activity O
of O
terminal B
deoxynucleotidyl I
transferase I
( O
TdT B
) O
, O
adenosine B
deaminase I
, O
and O
5 B
' I
nucleotidase I
and O
the O
cellular O
concentration O
of O
glucocorticoid B
( I
dexamethasone I
) I
receptor I
were O
determined O
in O
25 O
patients O
with O
acute O
non O
- O
lymphocytic O
leukaemia O
. O

Increased O
activity O
of O
TdT B
( O
greater O
than O
0 O
. O
1 O
unit O
/ O
microgram O
DNA O
) O
was O
found O
in O
11 O
patients O
. O

These O
results O
show O
that O
measurements O
of O
TdT B
activity O
and O
the O
glucocorticoid B
receptor I
concentration O
yield O
valuable O
prognostic O
information O
in O
acute O
non O
- O
lymphocytic O
leukaemia O

Evolution O
of O
a O
case O
of O
chronic O
lymphocytic O
leukemia O
( O
CLL O
) O
into O
blast O
crisis O
was O
found O
to O
be O
characterized O
by O
three O
unusual O
features O
( O
1 O
) O
the O
phenotype O
of O
the O
emerging O
blast O
cells O
was O
that O
of O
pre O
- O
plasmacytoid O
cells O
as O
shown O
by O
plasma O
cell O
morphology O
and O
an O
immunological O
phenotype O
corresponding O
partially O
with O
CLL O
- O
or O
intermediate O
B O
- O
cells O
, O
partially O
with O
plasma O
cells O
( O
terminal B
transferase I
- O
, O
common O
acute B
lymphocytic I
leukemia I
antigen I
- O
, O
Ia B
+ I
, O
surface B
immunoglobulin I
heavy I
chains I
- O
, O
surface B
kappa I
light I
chains I
+ O
, O

By O
contrast O
, O
neither O
the O
presence O
or O
absence O
nor O
the O
value O
of O
RPc B
could O
be O
related O
to O
cellularity O
or O
fibrosis O
. O

The O
value O
of O
REc B
and O
RPc B
analysis O
as O
an O
indicator O
of O
prognosis O
was O
examined O
in O
a O
sub O
- O
group O
of O
175 O
patients O
receiving O
no O
additional O
treatment O
following O
mastectomy O
. O

Activation O
of O
Jun B
N I
- I
terminal I
kinase I
or O
stress B
- I
activated I
kinase I
( O
JNK B
or O
SAPK B
) O
and O
mitogen B
- I
activated I
protein I
kinase I
( O
MAPK B
) O
and O
the O
induction O
of O
the O
transcription B
factor I
NF B
- I
ATc1 I
and I
egr I
- I
1 I
genes I
was O
normal O
. O

However O
, O
at O
24 O
hours O
, O
STAT4 O
heterodimerisation O
with O
STAT B
3 I
was O
only O
observed O
in O
spleen O
. O

We O
tested O
the O
hypothesis O
that O
biomechanical O
strain O
can O
induce O
expression O
of O
the O
class B
A I
scavenger I
receptor I
( O
SRA B
) O
, O
an O
important O
lipoprotein B
receptor I
in O
atherogenesis O
. O

METHODS O
AND O
RESULTS O
: O
Human O
monocyte O
/ O
macrophages O
or O
THP O
- O
1 O
cells O
were O
cultured O
in O
a O
device O
that O
imposes O
uniform O
biaxial O
cyclic O
1 O
- O
Hz O
strains O
of O
0 O
% O
, O
1 O
% O
, O
2 O
% O
, O
or O
3 O
% O
, O
and O
SRA B
expression O
was O
analyzed O
. O

Immunohistochemistry O
revealed O
that O
among O
macrophages O
in O
atherosclerotic O
lesions O
of O
the O
aorta O
, O
the O
proportion O
of O
macrophages O
with O
SRA B
expression O
was O
highest O
in O
hypertensive O
animals O
on O
a O
high O
- O
cholesterol O
diet O
( O
43 O
. O
9 O
+ O
/ O
- O
0 O
. O
7 O
% O
, O
versus O
12 O
. O
0 O
+ O
/ O
- O
2 O
. O
0 O
% O
for O
normotensive O
animals O
on O
a O
high O
- O
cholesterol O
diet O
and O
4 O
. O
7 O
+ O
/ O
- O
4 O
. O
7 O
% O
for O
animals O
on O
standard O
chow O
; O
P O
< O
0 O
. O
001 O
) O
. O

CONCLUSIONS O
: O
Biomechanical O
strain O
induces O
SRA B
expression O
by O
monocyte O
/ O
macrophages O
, O
suggesting O
a O
novel O
mechanism O
for O
promotion O
of O
atherosclerosis O
in O
hypertensive O
patients O
. O

Therefore O
CD8 B
alpha I
expression O
DCs O
does O
not O
indicate O
a O
lymphoid O
origin O
and O
differences O
among O
CD8 O
alpha O
+ O
and O
CD8 O
alpha O
- O
DCs O
might O
rather O
reflect O
maturation O
status O
than O
ontogeny O
. O

The O
Drosophila B
FOG I
homologue I
U I
- I
shaped I
( O
Ush B
) O
is O
expressed O
similarly O
in O
the O
blood O
cell O
anlage O
during O
embryogenesis O
. O

In O
this O
report O
, O
we O
show O
that O
Ush B
is O
expressed O
in O
hemocyte O
precursors O
and O
plasmatocytes O
throughout O
embryogenesis O
and O
larval O
development O
, O
and O
the O
GATA B
factor I
Serpent I
is O
essential O
for O
Ush B
embryonic O
expression O
. O

Furthermore O
, O
loss O
of O
ush O
function O
results O
in O
an O
overproduction O
of O
crystal O
cells O
, O
whereas O
forced O
expression O
of O
Ush B
reduces O
this O
cell O
population O
. O

When O
Ush B
, O
FOG B
- I
1 I
, O
FOG B
- I
2 I
, O
or O
mutant B
FOG I
- I
2 I
is O
coexpressed O
with O
Pnr B
during O
these O
developmental O
processes O
, O
severe O
eye O
and O
heart O
phenotypes O
result O
, O
consistent O
with O
a O
conserved O
negative O
regulation O
of O
Pnr B
function O
. O

The O
association O
of O
trans B
- I
acting I
T I
cell I
factors I
( O
TCFs B
) O
or O
lymphoid B
enhancer I
factor I
1 I
( O
LEF B
- I
1 I
) O
with O
their O
coactivator O
beta O
- O
catenin O
mediates O
transient O
transcriptional O
responses O
to O
extracellular O
Wnt O
signals O
. O

We O
report O
here O
that O
the O
60 B
- I
kDa I
catalytic I
subunit I
of O
calcineurin B
A I
( O
Cn B
A I
) O
was O
partially O
cleaved O
to O
a O
45 B
- I
kDa I
form O
in O
phytohemagglutinin O
A O
( O
PHA O
) O
or O
phorbol O
ester O
+ O
ionomycin O
( O
P O
+ O
I O
) O
- O
activated O
Jurkat O
cells O
. O

OX40 B
is O
a O
member O
of O
the O
tumor B
necrosis I
factor I
( I
TNF I
) I
receptor I
superfamily I
and O
known O
to O
be O
an O
important O
costimulatory B
molecule I
expressed O
on O
activated O
T O
cells O
. O

Invariant B
chain I
induces O
B O
cell O
maturation O
by O
activating O
a O
TAF B
( I
II I
) I
105 I
- I
NF I
- I
kappaB I
- O
dependent O
transcription O
program O
. O

Recently O
, O
invariant B
chain I
( O
Ii B
) O
, O
a O
major B
histocompatibility I
complex I
class I
II I
chaperone I
, O
as O
well O
as O
the O
transcription B
factors I
c B
- I
Rel I
and O
p65 B
/ I
RelA I
, O
were O
found O
to O
play O
a O
role O
in O
the O
final O
antigen O
- O
independent O
differentiation O
stage O
of O
B O
cells O
in O
the O
spleen O
. O

One O
of O
the O
most O
prominent O
glucocorticoid O
- O
induced O
genes B
is O
glucocorticoid B
- I
induced I
leucine I
zipper I
( O
GILZ B
) O
, O
which O
has O
been O
reported O
to O
inhibit O
activation O
- O
induced O
up O
- O
regulation O
of O
Fas B
ligand I
( I
FasL I
) I
mRNA I
. O

Indeed O
, O
transient O
expression O
of O
GILZ B
in O
Jurkat O
T O
cells O
blocked O
induction O
of O
a O
reporter B
construct I
driven O
by O
the O
FasL B
promoter I
. O

This O
could O
be O
accounted O
for O
by O
GILZ B
- O
mediated O
inhibition O
of O
Egr B
- I
2 I
and O
Egr B
- I
3 I
, O
NFAT B
/ I
AP I
- I
1 I
- O
inducible O
transcription B
factors I
that O
bind O
a O
regulatory B
element I
in O
the O
FasL B
promoter I
and O
up O
- O
regulate O
FasL O
expression O
. O

GILZ B
also O
potently O
inhibited O
AP B
- I
1 I
- I
driven I
and I
IL I
- I
2 I
promoter I
- I
driven I
reporter I
constructs I
, O
and O
recombinant O
GILZ B
specifically O
interacted O
with O
c B
- I
Fos I
and O
c B
- I
Jun I
in O
vitro O
and O
inhibited O
the O
binding O
of O
active B
AP I
- I
1 I
to O
its O
target O
DNA O
. O

Whereas O
homodimerization O
of O
GILZ B
required O
the O
presence O
of O
its O
leucine B
zipper I
, O
the O
interaction O
with O
c B
- I
Fos I
and O
c B
- I
Jun I
occurred O
through O
the O
N B
- I
terminal I
60 B
- I
amino I
acid I
region I
of O
GILZ B
. O

Thus O
, O
GILZ B
represents O
a O
glucocorticoid O
- O
induced O
gene O
product O
that O
can O
inhibit O
a O
variety O
of O
activation O
- O
induced O
events O
, O
at O
least O
in O
part O
by O
direct O
interference O
with O
AP B
- I
1 I
, O
and O
is O
therefore O
a O
candidate O
for O
a O
mediator O
of O
glucocorticoid O
- O
induced O
immunosuppression O
. O

Ig O
somatic O
mutations O
would O
be O
introduced O
by O
a O
polymerase B
( O
pol B
) O
while O
repairing O
DNA O
outside O
main O
DNA O
replication O
. O

Introduction O
of O
Tax B
into O
resting O
Kit O
225 O
cells O
induced O
activation O
of O
the O
G1 O
/ O
S O
transition O
regulation O
cascade O
consisting O
of O
activation O
of O
cyclin B
dependent I
kinase I
2 I
( O
CDK2 B
) O
and O
CDK4 B
, O
phosphorylation O
of O
the O
Rb B
family I
proteins I
and O
an O
increase O
in O
free O
E2F B
. O

The O
kinase O
activation O
was O
found O
to O
result O
from O
Tax B
- O
induced O
expression O
of O
genes O
for O
cell B
cycle I
regulatory I
molecules I
including O
cyclin B
D2 I
, O
cyclin B
E I
, O
E2F1 B
, O
CDK2 B
, O
CDK4 B
and O
CDK6 B
, O
and O
Tax B
- O
induced O
reduction O
of O
CDK B
inhibitors I
p19 I
( O
INK4d B
) O
and O
p27 B
( I
Kip1 I
) I
. O

Acyl B
- I
coenzyme I
A I
: I
cholesterol I
acyltransferase I
( O
ACAT B
) O
is O
an O
intracellular B
enzyme I
involved O
in O
cellular O
cholesterol O
homeostasis O
and O
in O
atherosclerotic O
foam O
cell O
formation O
. O

Human B
ACAT I
- I
1 I
gene I
contains O
two O
promoters B
( O
P1 B
and O
P7 B
) O
, O
each O
located O
in O
a O
different O
chromosome B
( I
1 I
and I
7 I
) I
( O
Li O
, O
B O
. O
L O
. O
, O
Li O
, O
X O
. O
L O
. O
, O
Duan O
, O
Z O
. O
J O
. O
, O
Lee O
, O
O O
. O
, O
Lin O
, O
S O
. O
, O
Ma O
, O
Z O
. O
M O
. O
, O
Chang O
, O
C O
. O
C O
. O
, O
Yang O
, O
X O
. O
Y O
. O
, O
Park O
, O
J O
. O
P O
. O
, O
Mohandas O
, O
T O
. O
K O
. O
, O
Noll O
, O
W O
. O
, O
Chan O
, O
L O
. O
, O
and O
Chang O
, O
T O
. O
Y O
. O
( O
1999 O
) O
J O
. O
Biol O
Chem O
. O

NF B
- I
kappaB I
and O
activator B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
activation O
were O
assessed O
by O
gel O
shift O
assay O
, O
and O
mRNA O
expression O
of O
interleukin B
- I
6 I
, O
tumor B
necrosis I
factor I
- I
alpha I
, O
KC O
, O
monocyte B
chemoattractant I
protein I
- I
1 I
, O
and O
inducible B
nitric I
oxide I
synthase I
was O
assessed O
by O
semiquantitative O
RT O
- O
PCR O
. O

A O
fifth O
member O
of O
the O
NFAT B
family I
, O
NFAT5 B
, O
controls O
the O
cellular O
response O
to O
osmotic O
stress O
, O
by O
a O
mechanism O
that O
requires O
dimer O
formation O
and O
is O
independent O
of O
calcineurin B
or O
of O
interaction O
with O
AP B
- I
1 I
. O

Expression O
of O
interferon B
consensus I
sequence I
binding I
protein I
induces O
potent O
immunity O
against O
BCR O
/ O
ABL O
- O
induced O
leukemia O
. O

Mice O
deficient O
in O
the O
interferon B
consensus I
sequence I
binding I
protein I
( O
ICSBP B
) O
develop O
a O
disease O
resembling O
chronic O
myeloid O
leukemia O
( O
CML O
) O
, O
which O
in O
humans O
is O
caused O
by O
the O
BCR B
/ I
ABL I
oncoprotein I
. O

EBV O
binds O
to O
CR2 B
through O
its O
major B
envelope I
glycoprotein I
- I
350 I
( O
gp350 B
) O
and O
is O
also O
a O
remarkable O
immunomodulating O
agent O
. O

To O
our O
knowledge O
this O
is O
the O
first O
report O
showing O
that O
the O
binding O
of O
a O
herpesvirus B
envelope I
glycoprotein I
to O
CR2 B
on O
human O
B O
cells O
results O
in O
the O
activation O
of O
the O
NF B
- I
kappaB I
transcription I
factor I
leading O
to O
the O
upregulation O
of O
IL O
- O
6 O
gene O
expression O
in O
these O
lymphocytes O
. O

Gads B
is O
a O
SH2 B
and I
SH3 I
domain I
- O
containing O
, O
hematopoietic B
- I
specific I
adaptor I
protein I
that O
functions O
in O
signalling O
from O
the O
T B
cell I
receptor I
. O

Gads B
acts O
by O
linking O
SLP B
- I
76 I
, O
bound O
by O
the O
carboxy B
- I
terminal I
Gads I
SH3 I
domain I
, O
to O
tyrosine B
phosphorylated I
LAT I
which O
contains O
binding O
sites O
for O
the O
Gads B
SH2 I
domain I
. O

Gads B
is O
distinguished O
from O
Grb2 B
and O
the O
closely O
related O
Grap B
protein I
by O
the O
presence O
of O
a O
120 B
amino I
acid I
unique I
region I
between O
the O
SH2 B
domain I
and O
the O
carboxy B
terminal I
SH3 I
domain I
. O

Here O
we O
demonstrate O
that O
the O
unique O
region O
of O
Gads B
contains O
a O
capase B
cleavage I
site I
. O

Induction O
of O
apoptosis O
in O
lymphocytes O
results O
in O
detectable O
Gads B
cleavage O
by O
60 O
min O
. O

Gads B
cleavage O
is O
blocked O
in O
vivo O
by O
treating O
cells O
with O
a O
caspase O
3 O
inhibitor O
. O

A O
putative B
caspase I
3 I
cleavage I
site I
was O
identified O
within O
the O
unique O
region O
and O
mutation O
of O
this O
site O
prevented O
Gads B
cleavage O
in O
vitro O
, O
and O
in O
vivo O
. O

The O
Gads B
cleavage O
products O
retained O
the O
predicted O
binding O
specificity O
for O
SLP B
- I
76 I
and O
LAT B
. O

Expression O
of O
the O
Gads B
cleavage O
products O
in O
Jurkat O
T O
cells O
inhibited O
NFAT O
activation O
following O
TCR O
cross O
linking O
. O

These O
findings O
indicate O
that O
cleavage O
of O
Gads B
in O
vivo O
could O
function O
to O
alter O
signalling O
downstream O
of O
the O
T B
cell I
receptor I
by O
disrupting O
cross O
talk O
between O
SLP B
- I
76 I
and O
LAT B
. O

Core B
- I
binding I
factor I
beta I
( O
CBFbeta B
) O
, O
but O
not O
CBFbeta B
- I
smooth I
muscle I
myosin I
heavy I
chain I
, O
rescues O
definitive O
hematopoiesis O
in O
CBFbeta B
- O
deficient O
embryonic O
stem O
cells O
. O

Core B
- I
binding I
factor I
beta I
( O
CBFbeta B
) O
is O
the O
non B
- I
DNA I
- I
binding I
subunit I
of O
the O
heterodimeric B
CBFs I
. O

Genes B
encoding I
CBFbeta I
( O
CBFB B
) O
, O
and O
one O
of O
the O
DNA B
- I
binding I
CBFalpha I
subunits I
, I
Runx1 I
( O
also O
known O
as O
CBFalpha2 B
, O
AML1 B
, O
and O
PEBP2alphaB B
) O
, O
are O
required O
for O
normal O
hematopoiesis O
and O
are O
also O
frequent O
targets O
of O
chromosomal O
translocations O
in O
acute O
leukemias O
in O
humans O
. O

Definitive O
hematopoiesis O
is O
restored O
by O
ectopic O
expression O
of O
full B
- I
length I
Cbfb I
transgenes I
, O
as O
well O
as O
by O
a O
transgene O
encoding O
only O
the O
heterodimerization B
domain I
of O
CBFbeta B
. O

In O
contrast O
, O
the O
CBFbeta B
- O
smooth B
muscle I
myosin I
heavy I
chain I
( I
SMMHC I
) I
fusion I
protein I
generated O
by O
the O
inv B
( I
16 I
) I
associated O
with O
acute O
myeloid O
leukemias O
( O
M4Eo O
) O
can O
not O
rescue O
definitive O
hematopoiesis O
by O
Cbfb O
- O
deficient O
ES O
cells O
. O

Sequences O
responsible O
for O
the O
inability O
of O
CBFbeta B
- O
SMMHC O
to O
rescue O
definitive O
hematopoiesis O
reside O
in O
the O
SMMHC B
portion I
of O
the O
fusion B
protein I
. O

Results O
also O
show O
that O
the O
CBFbeta B
- I
SMMHC I
fusion I
protein I
transdominantly O
inhibits O
definitive O
hematopoiesis O
, O
but O
not O
to O
the O
same O
extent O
as O
homozygous O
loss O
of O
Runx1 B
or O
Cbfb B
. O

Methionine B
adenosyltransferase I
( O
MAT B
) O
catalyzes O
the O
biosynthesis O
of O
S B
- I
adenosylmethionine I
( O
AdoMet B
) O
, O
a O
key O
molecule O
in O
transmethylation O
reactions O
and O
polyamine O
biosynthesis O
. O

We O
also O
found O
that O
NAC O
, O
PDTC O
, O
and O
SB203580 O
suppressed O
the O
activities O
of O
DEPs O
and O
their O
benzene O
extracts O
, O
suggesting O
the O
roles O
of O
oxidants O
- O
mediated O
NF O
- O
kappa O
B O
activation O
and O
p38MAPK B
pathways O
. O

Previously O
described O
binding O
sites O
for O
the O
cellular O
transcription B
factor I
Zif268 I
and O
the O
viral B
transactivator I
ZEBRA I
were O
found O
to O
be O
dispensable O
for O
activation O
of O
RpCAT B
by O
Rta B
. O

Runx2 B
: O
a O
novel O
oncogenic O
effector O
revealed O
by O
in O
vivo O
complementation O
and O
retroviral O
tagging O
. O

The O
Runx2 B
( O
Cbfa1 B
, O
Pebp2alphaA B
, O
Aml3 B
) O
gene O
was O
previously O
identified O
as O
a O
frequent O
target O
for O
transcriptional O
activation O
by O
proviral O
insertion O
in O
T O
- O
cell O
lymphomas O
of O
CD2 O
- O
MYC O
transgenic O
mice O
. O

We O
have O
recently O
shown O
that O
over O
- O
expression O
of O
the O
full O
- O
length O
, O
most O
highly O
expressed O
Runx2 B
isoform O
in O
the O
thymus O
perturbs O
T O
- O
cell O
development O
, O
leads O
to O
development O
of O
spontaneous O
lymphomas O
at O
low O
frequency O
and O
is O
strongly O
synergistic O
with O
Myc B
. O

To O
gain O
further O
insight O
into O
the O
relationship O
of O
Runx2 B
to O
other O
lymphomagenic O
pathways O
, O
we O
tested O
the O
effect O
of O
combining O
the O
CD2 B
- I
Runx2 I
transgene I
either O
with O
a O
Pim1 B
transgene I
( O
E B
( I
mu I
) I
- I
Pim1 I
) O
or O
with O
the O
p53 B
null O
genotype O
, O
as O
each O
of O
these O
displays O
independent O
synergy O
with O
Myc B
. O

However O
, O
Runx2 B
appeared O
to O
have O
a O
dominant O
effect O
on O
the O
tumour O
phenotype O
in O
each O
case O
, O
with O
most O
tumours O
conforming O
to O
the O
CD3 O
( O
+ O
) O
, O
CD8 O
( O
+ O
) O
, O
CD4 O
( O
+ O
/ O
- O
) O
phenotype O
seen O
in O
CD2 O
- O
Runx2 O
mice O
. O

These O
results O
indicate O
that O
Runx2 B
makes O
a O
distinct O
contribution O
to O
T O
- O
cell O
lymphoma O
development O
which O
does O
not O
coincide O
with O
any O
of O
the O
oncogene O
complementation O
groups O
previously O
identified O
by O
retroviral O
tagging O
. O

However O
, O
this O
lytic O
activity O
was O
significantly O
increased O
after O
blockade O
of O
p58 B
with O
specific O
monoclonal B
antibodies I
. O

Interestingly O
, O
we O
demonstrated O
that O
stimulation O
by O
tumor O
cells O
was O
required O
to O
trigger O
the O
inhibitory O
effect O
of O
p58 B
on O
the O
lytic O
activity O
of O
antigen O
- O
specific O
CTLs O
and O
that O
stimulation O
of O
the O
inhibitory O
function O
of O
p58 B
by O
tumor O
cells O
correlated O
with O
an O
inhibition O
of O
nuclear O
factor O
- O
kappaB O
activation O
in O
p58 O
+ O
tumor O
- O
specific O
CTLS O
. O

To O
study O
the O
mechanism O
by O
which O
protein B
tyrosine I
phosphatases I
( O
PTPs B
) O
regulate O
CD3 B
- O
induced O
tyrosine O
phosphorylation O
, O
we O
investigated O
the O
distribution O
of O
PTPs B
in O
subdomains O
of O
plasma O
membrane O
. O

We O
report O
here O
that O
the O
bulk O
PTP B
activity O
associated O
with O
T O
cell O
membrane O
is O
present O
outside O
the O
lipid O
rafts O
, O
as O
determined O
by O
sucrose O
density O
gradient O
sedimentation O
. O

Similar O
to O
transmembrane B
PTP I
, O
CD45 B
, O
the O
membrane O
- O
associated O
populations O
of O
SHP B
- I
1 I
and O
SHP B
- I
2 I
are O
essentially O
excluded O
from O
lipid O
rafts O
, O
where O
other O
signaling B
molecules I
such O
as O
Lck B
, I
linker I
for I
activation I
of I
T I
cells I
, O
and O
CD3 B
zeta I
are O
enriched O
. O

We O
further O
demonstrated O
that O
CD3 B
- O
induced O
tyrosine O
phosphorylation O
of O
these O
substrates O
is O
largely O
restricted O
to O
lipid O
rafts O
, O
unless O
PTPs B
are O
inhibited O
. O

It O
suggests O
that O
a O
restricted O
partition O
of O
PTPs B
among O
membrane O
subdomains O
may O
regulate O
protein O
tyrosine O
phosphorylation O
in O
T O
cell O
membrane O
. O

Collectively O
, O
these O
results O
suggest O
that O
the O
exclusion O
of O
PTPs B
from O
lipid O
rafts O
may O
be O
a O
mechanism O
that O
potentiates O
TCR B
/ O
CD3 B
activation O

We O
have O
shown O
that O
estrogen B
receptor I
( O
ERalpha B
, O
ERbeta B
) O
transcripts O
are O
expressed O
in O
SLE O
and O
normal O
T O
cells O
. O

The O
p38 B
MAP I
kinase I
as O
well O
as O
other O
members O
of O
the O
p38 O
MAP O
kinase O
pathway O
, O
including O
MKK3 B
, O
MKK6 B
, O
ATF B
- I
2 I
and O
Elk B
- I
1 I
, O
were O
activated O
in O
homocysteine O
- O
treated O
cells O
. O

Stromal B
cell I
- I
derived I
factor I
1 I
alpha I
( O
SDF1 B
alpha I
) O
and O
its O
cognate O
chemokine B
receptor I
CXCR4 I
act O
as O
potent O
chemoattractants O
and O
regulate O
trafficking O
and O
homing O
of O
hematopoietic O
progenitor O
cells O
and O
lymphocytes O
. O

AKT B
, O
which O
has O
been O
shown O
to O
mediate O
NO O
production O
, O
was O
also O
phosphorylated O
upon O
SDF1 B
alpha I
stimulation O
. O

Transcription O
of O
key O
target O
genes O
such O
as O
IRF1 B
and O
c B
- I
fos I
proceeds O
with O
delayed O
kinetics O
following O
CD2 O
stimulation O
, O
suggesting O
that O
this O
unique O
pattern O
of O
STAT O
activation O
may O
lead O
to O
a O
distinct O
cellular O
response O
following O
CD2 O
ligation O
. O

NFATc1 B
and O
NFATc2 B
together O
control O
both O
T O
and O
B O
cell O
activation O
and O
differentiation O
. O

To O
investigate O
further O
the O
two O
most O
prominent O
NFAT B
family I
members I
, O
NFATc1 B
and O
NFATc2 B
, O
we O
generated O
mice O
bearing O
lymphoid O
systems O
devoid O
of O
both O
. O

Thus O
, O
in O
T O
cells O
, O
NFATc1 B
and O
NFATc2 B
are O
dispensable O
for O
inflammatory O
reactivity O
but O
are O
required O
for O
effector O
differentiation O
, O
while O
in O
B O
cells O
, O
NFATs B
regulate O
both O
normal O
homeostasis O
and O
differentiation O
. O

Plasma B
tumor I
necrosis I
factor I
( I
TNF I
) I
- I
alpha I
, O
soluble B
intercellular I
adhesion I
molecule I
- I
1 I
( O
sICAM B
- I
1 I
) O
, O
monocyte B
chemoattractant I
protein I
- I
1 I
( I
MCP I
- I
1 I
) I
, O
plasminogen B
activator I
inhibitor I
type I
1 I
( O
PAI B
- I
1 I
) O
, O
C B
- I
reactive I
protein I
( I
CRP I
) I
, O
and O
interleukin B
( I
IL I
) I
- I
10 I
( O
antiinflammatory B
cytokine I
) O
concentrations O
were O
also O
measured O
as O
mediators O
of O
inflammatory O
activity O
that O
are O
regulated O
by O
the O
proinflammatory B
transcription I
factor I
NFkappaB I
. O

Plasma O
was O
used O
to O
measure O
insulin O
glucose O
, O
TNFalpha B
, O
sICAM B
, O
MCP B
- I
1 I
, O
PAI B
- I
1 I
, O
CRP B
, O
and O
IL B
- I
10 I
. O

The O
gene O
that O
encodes O
nuclear B
factor I
kappaB I
( I
NF I
- I
kappaB I
) I
essential I
modulator I
( O
or O
NEMO B
, O
also O
known O
as O
IKKgamma B
) O
is O
required O
for O
activation O
of O
the O
transcription B
factor I
NF I
- I
kappaB I
. O

Apoptosis O
induced O
by O
DMA O
- O
2 O
, O
4 O
- O
D O
was O
dose O
and O
time O
dependent O
, O
independent O
of O
Fas B
, O
TNF B
receptor I
1 I
or O
the O
aromatic B
hydrocarbon I
receptor I
, O
and O
involved O
disruption O
of O
the O
mitochondrial O
transmembrane O
potential O
and O
activation O
of O
caspase B
- I
9 I
. O

IL B
- I
6 I
upregulates O
suppressor B
of I
cytokine I
signaling I
1 I
( O
SOCS1 B
) O
expression O
in O
activated O
CD4 O
+ O
T O
cells O
, O
thereby O
interfering O
with O
signal B
transducer I
and I
activator I
of I
transcription I
1 I
( O
STAT1 B
) O
phosphorylation O
induced O
by O
interferon B
gamma I
( O
IFNgamma B
) O
. O

Additionally O
, O
sequence O
variation O
at O
C B
/ I
EBP I
site I
I I
, O
which O
lies O
immediately O
upstream O
of O
the O
distal B
nuclear I
factor I
kappa I
B I
site I
and O
immediately O
downstream O
of O
a O
binding O
site O
for O
activating B
transcription I
factor I
( O
ATF B
) O
/ O
cyclic B
AMP I
response I
element I
binding I
protein I
( O
CREB B
) O
, O
has O
been O
shown O
to O
affect O
HIV B
- I
1 I
long I
terminal I
repeat I
( O
LTR B
) O
activity O
. O

The O
Runt B
family I
transcription I
factor I
CBFalpha2 B
( O
AML1 B
, O
PEBP2alphaB B
, O
or O
Runx1 B
) O
is O
required O
by O
hematopoietic O
stem O
cells O
and O
expressed O
at O
high O
levels O
in O
T O
- O
lineage O
cells O
. O

In O
human O
T O
cells O
CBFalpha2 B
is O
usually O
transcribed O
from O
a O
different B
promoter I
( O
distal B
promoter I
) O
than O
in O
myeloid O
cells O
( O
proximal B
promoter I
) O
, O
but O
the O
developmental O
and O
functional O
significance O
of O
this O
promoter O
switch O
has O
not O
been O
known O
. O

Expression O
of O
the O
Ig B
J I
chain I
and O
the O
secreted O
form O
of O
Ig B
mu I
, O
which O
are O
both O
known O
to O
be O
suppressed O
by O
Pax B
- I
5a I
in O
mature O
B O
cells O
, O
were O
increased O
in O
B O
cells O
of O
aged O
mice O
. O

Sequential O
involvement O
of O
NFAT B
and O
Egr B
transcription B
factors I
in O
FasL O
regulation O
. O

The O
transcription B
factors I
Egr2 B
and O
Egr3 B
are O
potent O
activators O
of O
FasL O
expression O
. O

Here O
we O
find O
that O
Egr2 B
and O
Egr3 B
are O
NFAT B
target I
genes I
. O

Activation O
of O
FasL B
occurs O
via O
the O
NFAT B
- O
dependent O
induction O
of O
Egr3 B
, O
as O
demonstrated O
by O
the O
ability O
of O
exogenously O
provided O
NFATp B
to O
restore O
Egr B
- O
dependent O
FasL O
promoter O
activity O
in O
DKO O
lymph O
node O
cells O
. O

Further O
, O
Egr3 B
expression O
is O
enriched O
in O
Th1 O
cells O
, O
suggesting O
a O
molecular O
basis O
for O
the O
known O
preferential O
expression O
of O
FasL B
in O
the O
Th1 O
versus O
Th2 O
subset O
. O

We O
had O
previously O
shown O
that O
activation O
of O
the O
arylhydrocarbon B
receptor I
( O
AHR B
) O
, O
a O
member O
of O
the O
bHLH B
- I
PAS I
family I
of I
transcription I
factors I
, O
leads O
to O
increased O
mRNA O
expression O
of O
IL B
- I
2 I
in O
murine O
fetal O
thymocytes O
. O

Our O
results O
suggest O
that O
LIGHT B
is O
a O
costimulatory B
molecule I
involved O
in O
DC O
- O
mediated O
cellular O
immune O
responses O
. O

The O
physical O
association O
of O
protein B
kinase I
C I
theta I
with O
a O
lipid O
raft O
- O
associated O
inhibitor O
of O
kappa B
B I
factor I
kinase I
( I
IKK I
) I
complex I
plays O
a O
role O
in O
the O
activation O
of O
the O
NF O
- O
kappa O
B O
cascade O
by O
TCR B
and O
CD28 B
. O

We O
investigated O
the O
role O
of O
protein B
kinase I
C I
theta I
( O
PKCtheta B
) O
in O
the O
activation O
of O
the O
NF B
- I
kappaB I
cascade O
in O
primary O
human O
CD4 O
( O
+ O
) O
lymphocytes O
. O

The O
two O
latter O
phenomena O
were O
reproduced O
by O
the O
cross O
- O
linking O
of O
the O
alpha3 B
, O
alpha6 B
, O
beta1 B
and I
beta4 I
integrins I
, O
thus O
implying O
that O
the O
alpha3beta1 B
and I
alpha6beta4 I
heterodimers I
can O
signal O
during O
thymocyte O
adhesion O
. O

Using O
purified B
proteins I
, O
we O
have O
prepared O
a O
five O
- O
protein O
heterocomplex O
assembly O
system O
consisting O
of O
two O
proteins O
essential O
for O
heterocomplex O
assembly O
- O
hsp90 B
and O
hsp70 B
- O
and O
three O
proteins O
that O
act O
as O
co O
- O
chaperones O
to O
enhance O
assembly O
- O
Hop B
, O
hsp40 B
, O
p23 B
[ O
Morishima O
, O
Y O
. O
, O
Kanelakis O
, O
K O
. O
C O
. O
, O
Silverstein O
, O
A O
. O
M O
. O
, O
Dittmar O
, O
K O
. O
D O
. O
, O
Estrada O
, O
L O
. O
, O
and O
Pratt O
, O
W O
. O
B O
. O
( O
2000 O
) O
J O
. O
Biol O
. O
Chem O
. O
275 O
, O
6894 O
- O

The O
hsp70 B
co I
- I
chaperone I
Hip I
has O
been O
recovered O
in O
receptor B
. I
hsp90 I
heterocomplexes I
at O
an O
intermediate O
stage O
of O
assembly O
in O
reticulocyte O
lysate O
, O
and O
Hip B
is O
also O
thought O
to O
be O
an O
intrinsic O
component O
of O
the O
assembly O
machinery O
. O

Here O
we O
show O
that O
immunodepletion O
of O
Hip B
from O
reticulocyte O
lysate O
or O
addition O
of O
high O
levels O
of O
Hip B
to O
the O
purified O
five O
- O
protein O
system O
does O
not O
affect O
GR O
. O
hsp90 O
heterocomplex O
assembly O
or O
the O
activation O
of O
steroid O
binding O
activity O
that O
occurs O
with O
assembly O
. O

Despite O
the O
fact O
that O
Hip B
does O
not O
affect O
assembly O
, O
it O
is O
recovered O
in O
GR B
. I
hsp90 I
heterocomplexes I
assembled O
by O
both O
systems O
. O

In O
the O
five O
- O
protein O
system O
, O
Hip B
prevents O
inhibition O
of O
assembly O
by O
the O
hsp70 B
co I
- I
chaperone I
BAG I
- I
1 I
, O
and O
cotransfection O
of O
Hip B
with O
BAG B
- I
1 I
opposes O
BAG B
- I
1 I
reduction O
of O
steroid O
binding O
activity O
in O
COS O
cells O
. O

We O
conclude O
that O
Hip B
is O
not O
a O
component O
of O
the O
assembly O
machinery O
but O
that O
it O
could O
play O
a O
regulatory O
role O
in O
opposition O
to O
BAG B
- I
1 I
. O

Taken O
together O
, O
the O
data O
indicate O
that O
2 O
, O
2 O
' O
, O
4 O
, O
6 O
, O
6 O
' O
- O
PeCB O
induces O
apoptosis O
in O
human O
monocytic O
cells O
through O
a O
mechanism O
that O
is O
independent O
of O
the O
arylhydrocarbon B
receptor I
. O

We O
have O
previously O
reported O
that O
the O
activation O
of O
resting O
human O
immature O
peripheral O
blood O
T O
( O
PBT O
) O
lymphocytes O
is O
associated O
with O
the O
loss O
of O
retinoid B
X I
receptor I
alpha I
( O
RXRalpha B
) O
expression O
. O

In O
the O
present O
study O
, O
we O
have O
demonstrated O
that O
, O
unlike O
resting O
cells O
, O
activation O
of O
cycling O
human O
mature O
PBT O
lymphocytes O
, O
and O
T O
lymphocyte O
leukemia O
cell O
lines O
is O
accompanied O
by O
the O
accumulation O
of O
RXRalpha B
mRNA O
and O
protein O
. O

Interestingly O
, O
cyclosporin O
A O
further O
augmented O
RXRalpha B
expression O
, O
indicating O
the O
involvement O
of O
calcineurin O
pathways O
in O
the O
process O
. O

Transfection O
analysis O
in O
Jurkat O
cells O
, O
using O
RXRE O
- O
dependent O
reporter O
assays O
, O
showed O
that O
RXRalpha B
accumulated O
during O
T O
cell O
activation O
was O
transcriptionally O
inactive O
. O

These O
data O
demonstrate O
a O
dual O
regulatory O
control O
of O
RXRalpha B
expression O
during O
the O
activation O
of O
resting O
and O
cycling O
T O
lymphocytes O
and O
indicate O
a O
dynamic O
balance O
between O
JNK O
and O
ERK O
pathways O
in O
modulating O
RXRE O
- O
mediated O
transactivation O
. O

Csk B
, O
which O
phosphorylates O
tyrosine O
residues O
in O
the O
negative O
regulatory O
sites O
of O
Src B
family I
kinases I
, O
down O
- O
regulated O
Fyn O
- O
and O
Lck O
- O
mediated O
stimulation O
of O
the O
serum B
response I
element I
and O
Fyn O
- O
mediated O
enhancement O
of O
IL B
- I
2 I
promoter I
activity O
. O

These O
data O
suggest O
that O
Fyn B
and O
Lck B
, O
whose O
activities O
are O
regulated O
by O
Csk B
, O
are O
involved O
in O
different O
phases O
of O
T O
- O
cell O
activation O
. O

One O
of O
the O
binding B
factors I
possessed O
biochemical O
and O
immunological O
features O
identical O
to O
those O
of O
the O
transcription B
factor I
AP1 I
. O

We O
also O
demonstrate O
that O
TPB B
interaction O
with O
Rel B
activation I
regions I
leads O
to O
synergistic O
activation O
of O
transcription O
of O
a O
kappa B
B I
- I
linked I
reporter I
gene I
. O

To O
understand O
the O
mechanisms O
underlying O
the O
cell O
- O
type O
- O
specific O
expression O
of O
this O
gene O
, O
we O
have O
characterized O
the O
regulatory O
functions O
and O
the O
DNA O
- O
protein O
interactions O
of O
the O
5 B
' I
- I
flanking I
region I
of O
the O
mouse B
perforin I
gene I
( O
Pfp B
) O
. O

The O
synergistic O
induction O
of O
tyrosine O
phosphorylation O
by O
H2O2 O
plus O
vanadate O
included O
physiologically O
relevant O
proteins O
such O
as O
PLC B
gamma I
1 I
. O

Induction O
of O
tyrosine O
phosphorylation O
by O
ROI O
may O
thus O
lead O
to O
many O
of O
the O
pleiotropic O
effects O
of O
ROI O
in O
lymphoid O
cells O
, O
including O
downstream O
activation O
of O
PLC B
gamma I
1 I
and O
NF B
- I
kappa I
B I

Influence O
of O
sex B
hormone I
binding I
globulin I
and O
serum B
albumin I
on O
the O
conversion O
of O
androstenedione O
to O
testosterone O
by O
human O
erythrocytes O
. O

Double O
immunostaining O
with O
the O
anti B
- I
ER I
MAb I
and O
with O
specific B
MAb I
to O
detect O
different O
macrophage B
antigens I
( O
Ber B
- I
MAC3 I
, O
MAC387 B
, O
CD68 B
) O
and O
CD8 O
+ O
T O
cell O
subsets O
( O
CD29 O
+ O
, O
CD45RO O
+ O
and O
CD29 O
- O
, O
CD45RO O
- O
) O
was O
performed O
. O

